文献速递垂体与肾上腺疾病

原发性醛固酮增多症药物治疗后肾素状态与心血管、肾脏及死亡结局的系统综述与荟萃分析

Post-treatment renin status and cardiovascular, renal, and mortality outcomes in medically treated primary aldosteronism: a systematic review and meta-analysis.
PubMed 文献 · Lancet Diabetes Endocrinol · 2025-10-24

该系统综述与荟萃分析检索至2025年5月5日,纳入24项研究共6621例接受盐皮质激素受体拮抗剂治疗的原发性醛固酮增多症患者,其中5项研究贡献主要结局数据。

核心结论

  • 药物治疗后肾素未抑制与心血管事件及全因死亡风险降低相关,提示肾素正常化可能作为治疗目标。
  • 需前瞻性研究证实通过药物滴定使肾素正常化能否改善临床结局。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase、Cochrane Central及Web of Science至2025年5月5日。
  • 纳入24项研究共6621例接受盐皮质激素受体拮抗剂治疗的原发性醛固酮增多症患者,其中5项研究纳入主要结局荟萃分析。
  • 采用随机效应模型估计合并风险比(HR)及95%CI,使用QUIPS工具评估偏倚风险,方案在PROSPERO预注册(CRD42024598737)。

关键数值与推荐

  • 主要结局为心血管事件、肾脏事件及全因死亡发生率。

临床怎么用

  • 对接受盐皮质激素受体拮抗剂治疗的原发性醛固酮增多症患者,可监测治疗后肾素状态以评估抑制是否充分。
  • 肾素未抑制可能提示更好的心血管预后,但尚不能据此常规调整药物剂量,需前瞻性研究验证。

局限性

  • 无研究在所有QUIPS领域均评为低偏倚风险,许多研究在混杂偏倚领域存在高偏倚风险。
  • 主要结局荟萃分析仅纳入5项研究,部分结局证据确定性低或极低。
  • 研究多为观察性设计,无法确立因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Renin suppression persists in many patients with primary aldosteronism despite targeted medical treatment, which might indicate suboptimal mineralocorticoid receptor blockade. This study systematically reviewed the evidence for an association between post-treatment renin status and cardiovascular, renal, and mortality outcomes in medically treated primary aldosteronism. METHODS: For this systematic review and meta-analysis, MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Web of Science were searched from database inception up to May 5, 2025, for studies that investigated the association between post-treatment renin status and clinical outcomes among medically treated patients with primary aldosteronism. The primary outcomes were the incidence of cardiovascular events, renal events, and all-cause mortality. Risk-of-bias was assessed using the Quality in Prognostic Studies (QUIPS) tool. Random-effects models were employed to estimate pooled hazard ratios (HRs) with 95% CIs. The protocol was pre-registered on PROSPERO (CRD42024598737). FINDINGS: 3814 records were identified and 24 studies involving 6621 patients with primary aldosteronism on mineralocorticoid receptor antagonists were eligible and included, of which five studies contributed data to the meta-analyses of the primary outcomes. Most studies used plasma renin activity with a cut-off of 1·0 ng/mL per h to classify post-treatment renin as suppressed or unsuppressed. For the primary meta-analysis, individuals with unsuppressed post-treatment renin had a significantly lower risk of cardiovascular events compared with those with suppressed renin (pooled HR 0·43 [95% CI 0·23-0·80], I2=37%; four studies, 874 patients, low certainty of evidence). A subgroup meta-analysis demonstrated that unsuppressed post-treatment renin was associated with a significantly lower risk of cardiovascular events after 5 or more years of follow-up (pooled HR 0·33 [95%CI, 0·19-0·57], I2=0%, three studies, 754 patients; moderate certainty). No significant association was found with renal outcomes (pooled HR 0·95 [95% CI 0·51-1·77], two studies, I2=0%, very low certainty). One study reported a lower risk of all-cause mortality in patients with unsuppressed post-treatment renin than those with suppressed post-treatment renin (HR 0·29 [95% CI 0·09-0·98], 201 patients; low certainty). None of the studies were judged to have low risk of bias across all QUIPS domains, but many studies had high risk of bias in Domain 5 (bias due to confounding). INTERPRETATION: The association between unsuppressed renin following medical therapy for primary aldosteronism and reduced risk of cardiovascular events and all-cause mortality suggests that renin normalisation might serve as a therapeutic target. Prospective studies are required to formally confirm that medication titration to normalise renin improves clinical outcomes. FUNDING: None.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Katsuragawa S, Le MV, Fuller PJ, et al. Post-treatment renin status and cardiovascular, renal, and mortality outcomes in medically treated primary aldosteronism: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2025. PMID: 41235994. doi:10.1016/S2213-8587(25)00263-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。